flow trial semaglutide kidney outcomes 2024 nejm hazard ratio 🚨 Journal Club: Review 🚨 The FLOW Trial, published in The New England Journal of Medicine (May 2024), evaluated the effects of on disease in patients with type FLOW clinical Trial (funded by

BMJ 344:d7771 Vilsboll T, Knop FK, Krarup T et al (2003) The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype

Niksarli told me

43 Increasing evidence suggests that oxidative stress plays a role in the development and clinical manifestation of autism

The most common adverse events were gastrointestinal in nature, largely mild to moderate in severity and consistent with the GLP-1 receptor agonist (GLP-1RA) class

*Correspondence: Bin Cong, [email protected]

Here's what it does: Reduces Hunger: GLP-1 also tells your brain that you're full, which helps reduce your appetite